Clearside Biomedical is a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS). Co.'s SCS injection platform, utilizing its SCS Microinjector, enables non-surgical procedure for the targeted delivery of therapies to the macula, retina or choroid to preserve and improve vision in patients with sight-threatening eye diseases. Co. is utilizing its SCS injection platform by building a research and development pipeline targeting retinal diseases and by creating external collaborations with other companies. Co.'s product is XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use in therapy for macular edema. The CLSD stock yearly return is shown above.
The yearly return on the CLSD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CLSD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|